MabCure

MabCure Dividend

Dividend of MabCure (MBCI) as of Nov 4, 2026.

Dividend

0.00USD

Last updated:

How much dividend does MabCure 2026 pay?

According to the latest status from November 2026, MabCure paid a total of 0.00 USD per share in dividends within the last 12 months. With the current MabCure price of 0.00 USD, this corresponds to a dividend yield of - %. A dividend is paid times per year.

Historical MabCure Dividends

Historical MabCure Dividends
PaydateDividend

The MabCure Dividend history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Date
Dividend
Jan 1, 2006
0.00 USD
Jan 1, 2007
0.00 USD
Jan 1, 2008
0.00 USD
Jan 1, 2009
0.00 USD
Jan 1, 2010
0.00 USD
Jan 1, 2011
0.00 USD
The MabCure Dividend history
YEARDividendYoY
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—
0.00USD—

Is the MabCure Dividend Safe?

MabCure has been increasing the dividend for 0 years.

Analysts expect a Dividend Cut of -100.00% for the current fiscal year.

Dividend Details

Understanding MabCure's Dividend Distributions

MabCure’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining MabCure's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

MabCure's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in MabCure’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

MabCure Stock analysis

What does MabCure do? MabCure Inc is a company that focuses on the development of novel antibodies for the treatment of diseases. The company was founded in 2016 and is based in San Francisco. The founders of MabCure gathered their expertise in biotechnology and pharmaceutical companies before starting the firm. MabCure's business model includes the identification of therapeutic antibodies using innovative technologies. The company utilizes a platform developed by them to produce antibodies in a fast and cost-effective manner. MabCure has a broad patent portfolio and has the capability to license its technology to other companies. MabCure operates in different fields, with the main ones being oncology, neurology, and immunology. In oncology, the company focuses on the development of antibodies against cancers such as breast cancer, prostate cancer, and lung cancer. In neurology, MabCure conducts research on antibodies that can be used in diseases such as Alzheimer's, Parkinson's, and stroke. In immunology, the company develops antibodies that can support the immune system in autoimmune diseases such as lupus and rheumatoid arthritis. MabCure has several products in the pipeline tailored to the different fields. One of the most promising products is an antibody targeting the protein PD-L1. PD-L1 plays a crucial role in preventing the immune system's defense response against cancer cells. The MabCure antibody against PD-L1 has already been tested in clinical trials and has shown promising results. Another promising product is an antibody against a protein called tau, which accumulates in the brains of Alzheimer's patients. The MabCure antibody against tau is currently in preclinical development. MabCure collaborates closely with academic institutions and other companies to advance its technologies and products. The company has partnerships with leading pharmaceutical companies such as Merck and Pfizer to license and market its technologies. MabCure also has partnerships with academic institutions such as the University of California, San Francisco and Stanford University to conduct joint research projects. Overall, MabCure is a promising company that focuses on the development of novel antibodies for the treatment of diseases. The company has strong scientific expertise and utilizes innovative technologies to develop its products. Through its partnerships with other companies and academic institutions, MabCure is able to market and sell its technologies and products on a broad scale. MabCure is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MabCure stock

MabCure paid dividends every year for the past 0 years.

MabCure is assigned to the 'Health' sector.

The dividends of MabCure are distributed in USD.

Dividend calendar 2026

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

All Key Metrics — MabCure